The relationship between β-catenin and patient survival in colorectal cancer systematic review and meta-analysis.

B-catenin Colorectal cancer Disease free survival Meta-analysis Overall survival Systematic Review cancer specific cancer

Journal

Critical reviews in oncology/hematology
ISSN: 1879-0461
Titre abrégé: Crit Rev Oncol Hematol
Pays: Netherlands
ID NLM: 8916049

Informations de publication

Date de publication:
Jul 2021
Historique:
received: 08 12 2020
revised: 23 03 2021
accepted: 31 03 2021
pubmed: 17 5 2021
medline: 14 7 2021
entrez: 16 5 2021
Statut: ppublish

Résumé

β-catenin is a key component of Wnt signalling, which plays a crucial role in CRC progression. Therefore, a meta-analysis was performed to assess the prognostic value of β-catenin expression in CRC patients. PubMed and Web of Science were searched for relevant publications referring to the association between β-catenin expression and outcome of CRC patients. Review Manager version 5.4 was employed to analysis data from 28 eligible studies (containing 5475 patients). Of these, 6 provided data on DFS, 6 provided data on CSS and 18 reports provided data on OS. High nuclear β-catenin expression was significantly associated with poorer DFS, CSS and OS in patients with CRC whereas, low membranous β-catenin expression was associated to poor OS. In conclusion, β-catenin has prognostic value and potential as a biomarker to stratify patients with CRC. However, further work with high quantity tissue cohorts and patient data is required to confirm this conclusion.

Identifiants

pubmed: 33992802
pii: S1040-8428(21)00125-6
doi: 10.1016/j.critrevonc.2021.103337
pii:
doi:

Substances chimiques

beta Catenin 0

Types de publication

Journal Article Meta-Analysis Review Systematic Review

Langues

eng

Sous-ensembles de citation

IM

Pagination

103337

Informations de copyright

Copyright © 2021 Elsevier B.V. All rights reserved.

Auteurs

Amna Matly (A)

Unit of Experimental Therapeutics, Institute of Cancer Sciences, University of Glasgow, Wolfson Wohl Cancer Research Centre, Garscube Estate, Glasgow, G61 1QH, United Kingdom. Electronic address: 2427560m@student.gla.ac.uk.

Jean A Quinn (JA)

Unit of Experimental Therapeutics, Institute of Cancer Sciences, University of Glasgow, Wolfson Wohl Cancer Research Centre, Garscube Estate, Glasgow, G61 1QH, United Kingdom. Electronic address: Jean.Quinn@glasgow.ac.uk.

Donald C McMillan (DC)

Academic Unit of Surgery, School of Medicine, University of Glasgow, Glasgow Royal Infirmary, Alexandria Parade, Glasgow, G31 2ER, United Kingdom. Electronic address: Donald.McMillan@glasgow.ac.uk.

James H Park (JH)

Academic Unit of Surgery, School of Medicine, University of Glasgow, Glasgow Royal Infirmary, Alexandria Parade, Glasgow, G31 2ER, United Kingdom. Electronic address: James.Park@glasgow.ac.uk.

Joanne Edwards (J)

Unit of Experimental Therapeutics, Institute of Cancer Sciences, University of Glasgow, Wolfson Wohl Cancer Research Centre, Garscube Estate, Glasgow, G61 1QH, United Kingdom. Electronic address: joanne.edwards@glasgow.ac.uk.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH